RxDoctor Payments DataLook up a doctor →

Charles Hilgenhurst, MD

Pain Medicine · Smyrna, TNNPI 1114966355

Payments from drug & device makers

$16,313in general payments, 2019–2025

Across 700 payments — averaging $23.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$4K
  • Boston Scientific$2K
  • Collegium Pharmaceutical, Inc.$1K
  • Nevro Corp.$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • SPR Therapeutics, Inc$921
  • plus $5K from 38 others

What the payments were for

  • Travel & lodging$1,80911%
  • Food & beverage$14,48789%
  • Entertainment$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,313 in reported general payments places this provider in the 80th percentile of 112 pain medicine providers in Tennessee.

See all pain medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$198,348
Medicare patients
302
Services billed
2,079

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate151$74,478
OxycontinOxycodone Hcl89$65,475
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen821$22,248
MovantikNaloxegol Oxalate35$14,704
Oxycodone Hcl674$14,498
LyricaPregabalin12$13,200
BelbucaBuprenorphine Hcl14$12,625
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen504$12,223
Oxymorphone Hcl ErOxymorphone Hcl30$11,703
Fentanyl89$11,385
Morphine Sulfate ErMorphine Sulfate398$10,903
Gabapentin624$6,816
Pregabalin222$4,350
Tizanidine Hcl205$1,555
Naloxone Hcl17$1,033

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$1,456$87,103165 claims
Redhill Biopharma Inc.Movantik$41$14,70435 claims
PfizerLyrica$73$13,20012 claims
Hikma Pharmaceuticals USAMorphine Sulfate$16$57516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 112 pain medicine providers in Tennessee.

Other pain medicine in Smyrna

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →